Bank of America Has Lowered Expectations for LENZ Therapeutics (NASDAQ:LENZ) Stock Price

LENZ Therapeutics (NASDAQ:LENZ) had its price objective reduced by analysts at Bank of America from $35.00 to $29.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Bank of America‘s price objective suggests a potential upside of 216.70% from the stock’s current price.

Several other analysts have also recently issued reports on the company. HC Wainwright reiterated a “buy” rating on shares of LENZ Therapeutics in a research note on Monday, December 15th. Wall Street Zen downgraded LENZ Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LENZ Therapeutics in a report on Thursday, January 22nd. Finally, William Blair reiterated an “outperform” rating on shares of LENZ Therapeutics in a report on Tuesday, March 10th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $50.20.

LENZ Therapeutics Stock Performance

Shares of LENZ stock opened at $9.16 on Wednesday. LENZ Therapeutics has a fifty-two week low of $8.85 and a fifty-two week high of $50.40. The company has a 50 day moving average price of $14.33 and a 200 day moving average price of $24.51. The stock has a market capitalization of $286.52 million, a P/E ratio of -4.35 and a beta of 0.52.

LENZ Therapeutics (NASDAQ:LENZ) last released its earnings results on Tuesday, March 24th. The company reported ($1.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.25). The business had revenue of $1.59 million for the quarter, compared to the consensus estimate of $3.09 million. On average, research analysts forecast that LENZ Therapeutics will post -2.18 EPS for the current fiscal year.

Institutional Investors Weigh In On LENZ Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Intech Investment Management LLC grew its holdings in shares of LENZ Therapeutics by 4.3% during the second quarter. Intech Investment Management LLC now owns 9,251 shares of the company’s stock worth $271,000 after purchasing an additional 380 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of LENZ Therapeutics by 51.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company’s stock valued at $41,000 after purchasing an additional 477 shares during the period. Quarry LP purchased a new position in LENZ Therapeutics during the 3rd quarter worth approximately $27,000. Ameritas Investment Partners Inc. increased its position in LENZ Therapeutics by 47.6% during the second quarter. Ameritas Investment Partners Inc. now owns 1,817 shares of the company’s stock worth $53,000 after buying an additional 586 shares during the period. Finally, Bfsg LLC purchased a new stake in LENZ Therapeutics in the third quarter valued at approximately $30,000. 54.32% of the stock is owned by hedge funds and other institutional investors.

LENZ Therapeutics News Roundup

Here are the key news stories impacting LENZ Therapeutics this week:

• Positive Sentiment: Management says the newly launched LNZ100 has exceeded commercial expectations and positions the company for a larger market opportunity, which could support future revenue upside. LENZ Therapeutics Surpasses Expectations with LNZ100 Launch
• Positive Sentiment: Company highlighted a strong cash position and outlined an acceleration strategy for 2026 on the earnings call, which may provide runway for commercialization and R&D investments. LENZ Q4 2025 Earnings Call Highlights
• Positive Sentiment: LENZ is expanding its VIZZ sales force to 117 reps, a concrete commercial investment that could help convert product demand into sales over coming quarters. Lenz expands VIZZ sales force
• Neutral Sentiment: The full Q4 earnings call transcript and company press release are available for review (useful for detail on guidance, cash runway and commercialization cadence). Earnings Call Transcript
• Neutral Sentiment: Multiple short-interest reports show zero shares / NaN changes and a 0.0 days-to-cover metric — this appears to be data noise rather than meaningful short activity, so it is unlikely to explain today’s move.
• Negative Sentiment: Q4 results missed: EPS of ($1.16) vs. consensus ($0.91) and revenue $1.59M versus $3.09M expected — the earnings and revenue shortfall is the primary near‑term catalyst pushing the stock lower. Q4 loss, misses revenue estimates
• Negative Sentiment: Market reports note shares hit an all‑time low after the underwhelming 4Q sales report, which can trigger additional selling and weigh on investor sentiment. Shares hit all-time low
• Negative Sentiment: Technically the stock is trading well below its 50‑day ($14.33) and 200‑day ($24.51) moving averages and near its 52‑week low, magnifying downside pressure until clarity on sales trajectory and revenue growth is delivered.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.